NKTR
Nektar Therapeutics
NASDAQ · USHealthcareBiotechnology
$64.84-5.01%
Price as of Jul 20, 2026
NKTR growth
Nektar Therapeutics growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -36.2%
- EBITDA
- -28.5%
- EBIT
- -9.5%
- EPS
- +11.6%
- Free cash flow
- -14.5%
- Operating cash flow
- -15.2%
Forward estimates
- Revenue
- -17.4%
- EBITDA
- +64.4%
- EPS
- -44.1%
Three-year CAGR
- Revenue
- -15.7%
- EBITDA
- -58.0%
- EBIT
- -24.3%
- Net income
- -37.9%
- EPS
- -12.1%
- Free cash flow
- -17.8%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.